Latest News from ASCO in Action

Latest News from ASCO in Action

December 19, 2014

On December 19, 2014, the U. S. Food and Drug Administration approved olaparib capsules (LynparzaTM, AstraZeneca Pharmaceuticals LP) as monotherapy for the treatment of patients with deleterious or suspected deleterious germline BRCA mutated (gBRCAm) (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. 

December 18, 2014

The International Association for the Study of Lung Cancer (IASLC) is hosting a webinar on January 21, 2015, that will discuss the clinical effects of continued smoking in lung cancer patients, including the impact of smoking on cancer cell biology.

ASCO's ACT Network

ASCO's ACT Network

ALERT CONGRESS TODAY! Use ASCO's ACT Network to contact your elected officials on important policy issues impacting cancer care. 

ASCO Issue Backgrounders

ASCO Issue Backgrounders

ASCO offers issue backgrounders to help provide an overview of the major policy issues that impact patients with cancer and the physicians who care for them. The issue backgrounders cover topics such as reimbursement, health equity, cancer research funding, and more.

Click here to read the backgrounds and help develop your understanding of cancer policy issues.

NIH Funding Educational Series

NIH Funding Educational Series

ASCO explores the decade-long decline in federal funding for cancer research – and why this decline must be reversed. Read more here.